Patents Assigned to Exthera Medical Corporation
-
Patent number: 10188783Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: GrantFiled: August 16, 2017Date of Patent: January 29, 2019Assignee: ExThera Medical CorporationInventors: Olle Larm, Tomas Bergstrom
-
Publication number: 20180361050Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Applicant: EXTHERA MEDICAL CORPORATIONInventors: ROBERT S. WARD, Keith R. McCREA, Olle LARM, Lars ADOLFSSON
-
Patent number: 10086126Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: June 30, 2016Date of Patent: October 2, 2018Assignee: ExThera Medical CorporationInventors: Robert S Ward, Keith R McCrea, Olle Larm, Lars Adolfsson
-
Publication number: 20170340803Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: ApplicationFiled: August 16, 2017Publication date: November 30, 2017Applicant: ExThera Medical CorporationInventors: Olle LARM, Tomas Bergstrom
-
Patent number: 9764077Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: GrantFiled: October 1, 2015Date of Patent: September 19, 2017Assignee: EXTHERA MEDICAL CORPORATIONInventors: Olle Larm, Tomas Bergstrom
-
Patent number: 9669150Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.Type: GrantFiled: January 15, 2014Date of Patent: June 6, 2017Assignee: EXTHERA MEDICAL CORPORATIONInventors: Olle Larm, Tomas Bergstrom, Jonas Axelsson, Lars Adolfsson, Robert S. Ward, Keith McCrae
-
Publication number: 20160331886Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: June 30, 2016Publication date: November 17, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: ROBERT S. WARD, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 9408962Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: April 24, 2014Date of Patent: August 9, 2016Assignee: EXTHERA MEDICAL CORPORATIONInventors: Robert S. Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Publication number: 20160101229Abstract: A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.Type: ApplicationFiled: December 17, 2015Publication date: April 14, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: KEITH MCCREA, ROBERT WARD, OLLE LARM, LARS ADOLFSSON
-
Publication number: 20160082177Abstract: The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit.Type: ApplicationFiled: September 21, 2015Publication date: March 24, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: ROBERT S. WARD, KEITH R. McCREA
-
Publication number: 20160084835Abstract: The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.Type: ApplicationFiled: October 16, 2015Publication date: March 24, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: ROBERT S. WARD, Keith R. McCrea
-
Publication number: 20160022898Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: ApplicationFiled: October 1, 2015Publication date: January 28, 2016Applicant: EXTHERA MEDICAL CORPORATIONInventors: OLLE LARM, TOMAS BERGSTROM
-
Patent number: 9173989Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: GrantFiled: December 13, 2006Date of Patent: November 3, 2015Assignee: EXTHERA MEDICAL CORPORATIONInventors: Olle Larm, Tomas Bergström
-
Publication number: 20140231357Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: ApplicationFiled: April 24, 2014Publication date: August 21, 2014Applicant: EXTHERA MEDICAL CORPORATIONInventors: Robert S Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 8758286Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: December 1, 2010Date of Patent: June 24, 2014Assignee: Exthera Medical CorporationInventors: Robert S Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 8663148Abstract: The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.Type: GrantFiled: June 18, 2008Date of Patent: March 4, 2014Assignee: Exthera Medical CorporationInventors: Olle Larm, Tomas Bergström, Jonas Axelsson, Lars Adolfsson, Robert S. Ward, Keith McCrea